Health Catalyst, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 8, 2020 (with events reported through April 14, 2020), details Health Catalyst, Inc.'s entry into a material definitive agreement involving the issuance of convertible debt and the termination of prior credit facilities. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Capital Structure Changes
- Debt Issuance: Issued $230.0 million in aggregate principal amount of 2.50% Convertible Senior Notes due 2025. This includes a $30.0 million upsized portion.
- Interest Rate: Notes accrue interest at 2.50% per year, payable semiannually.
- Conversion Terms: Initial conversion rate is 32.6797 shares per $1,000 principal amount (approx. $30.60 per share).
- Debt Repayment:
- Repaid Silicon Valley Bank (SVB) in full for $30,209.44.
- Prepaid $57,207,444.44 to fully retire indebtedness under the OrbiMed Credit Agreement.
- Capped Call Transactions: Used approximately $21.6 million of net proceeds to fund capped call transactions with a cap price of $42.00 per share to offset potential dilution.
Material Changes Versus Prior Period
The filing represents a significant shift in the Company's capital structure. The Company replaced a high-interest term loan facility (OrbiMed) carrying an interest rate of LIBOR plus 7.5% or 10.0% with lower-cost convertible debt at 2.50%. Additionally, the Company eliminated a smaller secured loan with SVB. The filing does not provide comparative revenue, profit, or cash flow metrics as this is a transactional report rather than a periodic financial statement.
Outlook, Risks, and Management Commentary
- Redemption Rights: The Company may not redeem the Notes prior to April 20, 2023. Redemption is permitted thereafter if the stock price exceeds 130% of the conversion price for a specified period.
- Conversion Triggers: Holders may convert notes prior to October 15, 2024, only under specific circumstances, such as significant stock price appreciation (130% of conversion price) or a fundamental change.
- Subordination: The Notes are senior unsecured obligations but are structurally junior to all indebtedness of the Company's subsidiaries.
- Use of Proceeds: Proceeds were utilized to repay existing debt, fund capped call transactions, and for general corporate purposes.
Key Facts for Investor Verification
- Verify the impact of the $21.6 million cost of capped call transactions on net cash proceeds.
- Confirm the dilution profile based on the initial conversion price of $30.60 versus the current market price.
- Review the specific terms of the "fundamental change" repurchase option to understand potential cash outflows in M&A scenarios.
- Assess the reduction in interest expense resulting from replacing the OrbiMed loan (up to 10% interest) with the 2.50% Notes.